Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

ALRN


Top 10 Correlated ETFs

ALRN


Top 10 Correlated Stocks

ALRN


In the News

01:34 29 Nov 2022 ALRN

Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade

Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

08:00 29 Nov 2022 ALRN

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.

06:00 29 Nov 2022 ALRN

Penny Stocks to Buy on August 8th? 3 to Watch

Here's what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:30 29 Nov 2022 ALRN

How to Trade Penny Stocks in August 2022

What you need to know about trading penny stocks in August The post How to Trade Penny Stocks in August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:40 29 Nov 2022 ALRN

3 Oversold Biotech Stocks to Buy Now

Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.

07:00 29 Nov 2022 ALRN

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.

11:19 29 Nov 2022 ALRN

Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?

Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

11:18 29 Nov 2022 ALRN

Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?

Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

08:45 29 Nov 2022 ALRN

Aileron Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th – 12th and the Emerging Growth Conference, which will be held virtually on January 5th. Details of the upcoming Aileron presentations are as follows:

09:22 29 Nov 2022 ALRN

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924's activation of p21-induced cell cycle arrest in murine bone marrow cells and epithelial mucosa cells in the gastrointestinal (GI) tract --

Financial details

Company Rating
Neutral
Market Cap
13.08M
Income
-29.58M
Revenue
0
Book val./share
5
Cash/share
5.61
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
01 Nov 2022
P/E
-9.44
Forward P/E
-
PEG
2.04
P/S
-
P/B
0.58
P/C
0.5
P/FCF
-0.38
Quick Ratio
5.62
Current Ratio
5.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.52
EPS next Y
-
EPS next Q
-
EPS this Y
9.66%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.45%
-
-
-
-
SMA20
-23.44%
SMA50
-31.17%
SMA100
-48.75%
Inst Own
31.15%
Inst Trans
-4.23%
ROA
-109%
ROE
-90%
ROC
-1.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
90.82M
Shs Float
58.5M
-
-
-
-
Target Price
-
52W Range
2.58-15.0
52W High
-81.33%
52W Low
+40%
RSI
31.62
Rel Volume
0.47
Avg Volume
42.96K
Volume
20.21K
Perf Week
-15.92%
Perf Month
-31.37%
Perf Quarter
-67.67%
Perf Half Y
-66.82%
-
-
-
-
Beta
1.96518
-
-
Volatility
0.21%, 0.47%
Prev Close
-2.78%
Price
2.8
Change
-4.04%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-60.74-42.81-23.94-12.14-13.31
Operating cash flow per share
-55.17-37.9-21.58-11.75-12.08
Free cash flow per share
-55.55-43.9-21.7-11.75-12.16
Cash per share
136.3728.0814.97.9223.36
Book value per share
128.4326.613.086.9822.33
Tangible book value per share
128.4326.613.086.9822.33
Share holders equity per share
128.4326.613.086.9822.33
Interest debt per share
000.360.220.08
Market cap
3.44M795.86K877.27K3.19M819.06K
Enterprise value
-8.42M-9.84M-3.99M-3.47M-2.62M
P/E ratio
-0.15-0.03-0.03-0.15-0.03
Price to sales ratio
00000
POCF ratio
-0.17-0.03-0.03-0.16-0.03
PFCF ratio
-0.17-0.02-0.03-0.16-0.03
P/B Ratio
0.070.040.050.260.02
PTB ratio
0.070.040.050.260.02
EV to sales
00000
Enterprise value over EBITDA
0.370.310.130.180.1
EV to operating cash flow
0.410.350.150.170.11
EV to free cash flow
0.410.30.150.170.11
Earnings yield
-6.57-39.64-33.48-6.63-31.94
Free cash flow yield
-6.01-40.65-30.35-6.42-29.19
Debt to equity
0000.020
Debt to assets
0.090.350.390.260.09
Net debt to EBITDA
0.520.340.160.340.13
Current ratio
10.64.053.354.1210.69
Interest coverage
00000
Income quality
0.910.890.90.970.91
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.160.0100.01
Capex to revenue
00000
Capex to depreciation
-1.1-20.29-0.97-0.03-1.3
Stock based compensation to revenue
00000
Graham number
418.95160.0683.9443.6581.77
ROIC
-0.48-1.28-1.45-1.66-0.61
Return on tangible assets
-0.43-1.04-1.11-1.29-0.54
Graham Net
123.2313.556.45.5221.03
Working capital
46.95M16.41M13.71M12.37M43.67M
Tangible asset value
00000
Net current asset value
46.95M11.06M9.13M12.15M43.6M
Invested capital
000.030.030
Average receivables
00000
Average payables
1.6M1.66M1.52M1.6M1.4M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.47-1.61-1.83-1.74-0.6
Capex per share
-0.38-6-0.120-0.08

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
00000
Net income per share
-1.48-1.5-1.86-1.76-1.4
Operating cash flow per share
-1.6-1.38-1.72-2.97-1.54
Free cash flow per share
-1.6-1.38-1.72-2.97-1.54
Cash per share
11.5410.158.47.135.61
Book value per share
11.079.77.966.35
Tangible book value per share
11.079.77.966.35
Share holders equity per share
11.079.77.966.35
Interest debt per share
0.040.040.030.020.04
Market cap
4.62M2.55M2.32M1.18M938.66K
Enterprise value
-2.79M-889.5K-4.99M-6.35M-3.83M
P/E ratio
-0.17-0.09-0.07-0.04-0.04
Price to sales ratio
00000
POCF ratio
-0.64-0.41-0.3-0.09-0.13
PFCF ratio
-0.64-0.41-0.3-0.09-0.13
P/B Ratio
0.090.060.060.040.04
PTB ratio
0.090.060.060.040.04
EV to sales
00000
Enterprise value over EBITDA
0.410.130.60.80.6
EV to operating cash flow
0.380.140.640.470.55
EV to free cash flow
0.380.140.640.470.55
Earnings yield
-1.45-2.67-3.63-6.77-6.78
Free cash flow yield
-1.57-2.45-3.36-11.42-7.43
Debt to equity
00000
Debt to assets
0.090.090.10.150.17
Net debt to EBITDA
1.10.510.870.940.74
Current ratio
11.9310.699.656.515.96
Interest coverage
00-4010-58.93
Income quality
1.080.920.931.691.09
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.130000
Stock based compensation to revenue
00000
Graham number
19.218.118.2515.812.56
ROIC
-0.14-0.16-0.23-0.28-0.29
Return on tangible assets
-0.12-0.14-0.21-0.24-0.23
Graham Net
10.519.137.4864.61
Working capital
49.86M43.67M35.85M28.4M22.52M
Tangible asset value
00000
Net current asset value
49.76M43.6M35.85M28.4M22.52M
Invested capital
00000
Average receivables
00000
Average payables
1.39M1.48M1.38M1.74M1.34M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.13-0.15-0.23-0.28-0.28
Capex per share
00000

Frequently Asked Questions

What is Aileron Therapeutics, Inc. stock symbol ?

Aileron Therapeutics, Inc. is a US stock , located in Watertown of Massachusetts and trading under the symbol ALRN

What is Aileron Therapeutics, Inc. stock quote today ?

Aileron Therapeutics, Inc. stock price is $2.8 today.

Is Aileron Therapeutics, Inc. stock public?

Yes, Aileron Therapeutics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap